待地产企稳驱动收入回升，AI 规划积极提供估值弹 2025 年 03 月 29 日 投资评级：买入（维持） | 日期 | 2025/3/28 | | --- | --- | | 当前股价(港元) | 3.050 | | 一年最高最低(港元) | 4.650/1.570 | | 总市值(亿港元) | 59.29 | | 流通市值(亿港元) | 58.91 | | 总股本(亿股) | 19.44 | | 流通港股(亿股) | 19.32 | | 近 3 个月换手率(%) | 69.71 | 公 司 信 息 更 新 报 告 计算机/软件开发 公 司 研 究 明源云（00909.HK） 股价走势图 数据来源：聚源 -60% -30% 0% 30% 60% 90% 120% 2024-04 2024-08 2024-12 明源云 恒生指数 相关研究报告 | 吴柳燕（分析师） | 杨哲（分析师） | | --- | --- | | wuliuyan@kysec.cn | yangzhe@kysec.cn | | 证书编号：S0790521110001 | 证书编号：S0790524100001 | 证书编号：S07905 ...

社会服务/酒店餐饮 数据来源：聚源 相关研究报告 《翻台显著增长，换帅后期待开店和 多品牌拓展加速—公司信息更新报 告》-2024.9.1 《经营业绩亮眼，提质增效多区域本 土化成果显著—公司信息更新报告》 -2024.3.29 初敏（分析师） 李睿娴（分析师） liruixian@kysec.cn 特海国际（09658.HK） 经营效率提升亮眼，关注多元品牌孵化和北美拓展 2025 年 03 月 29 日 投资评级：买入（维持） | 日期 | 2025/3/28 | | --- | --- | | 当前股价(港元) | 17.800 | | 一年最高最低(港元) | 24.100/10.940 | | 总市值(亿港元) | 115.75 | | 流通市值(亿港元) | 115.75 | | 总股本(亿股) | 6.50 | | 流通港股(亿股) | 6.50 | | 近 3 个月换手率(%) | 10.73 | 股价走势图 -40% -20% 0% 20% 40% 60% 80% 2024-04 2024-08 2024-12 特海国际 恒生指数 "红石榴"和北美拉动门店新开加速，供应链&门店管理优化餐厅利 ...

2025 年 03 月 29 日 业绩短期承压，期待原奶价格回升 买入(首次) 事件 分析师：孙山山 S1050521110005 sunss@cfsc.com.cn 联系人：肖燕南 S1050123060024 xiaoyn@cfsc.com.cn 基本数据 | 当前股价 | （港元） | 1.13 | | --- | --- | --- | | 总市值 | （亿港元） | 89.4 | | 总股本 | （百万股） | 7,915.7 | | 流通股本 | （百万股） | 7,915.7 | | 52周价格区间 | （港元） | 0.6-1.31 | | 日均成交额 | （百万港元） | 8.6 | 市场表现 资料来源：Wind，华鑫证券研究 -10% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 现代牧业 恒生指数 相关研究 —现代牧业（1117.HK）公司事件点评报告 2025 年 3 月 25 日，现代牧业发布 2024 年年报。 投资要点 ▌ 利润短期承压，现金流表现较好 收入符合预期，非现金项目拖累利润。2024 年公司实现营收 132.54 亿元，同减 1.5%； ...

2025 年 3 月 28 日 公司研究 车险承保稳健，投资推升业绩 ——中国财险（2328.HK）2024 年年报点评 买入（维持） 当前价：14.40 港元 作者 分析师：王一峰 执业证书编号：S0930519050002 010-57378038 wangyf@ebscn.com 分析师：黄怡婷 执业证书编号：S0930524070003 010-57378023 huangyiting@ebscn.com 市场数据 | 总股本(亿股) | 222.43 | | --- | --- | | 总市值(亿元港币)： | 3202.96 | | 一年最低/最高(元港币)： | 8.96/15.12 | | 近 3 月换手率： | 49.6% | 股价相对走势 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | 7.4 | 1.2 | 8.8 | | 绝对 | 5.9 | 17.8 | 50.4 | | 资料来源：Wind | | | | 相关研报 首次实施中期分红，COR 维持良好水平—— ——中国财险（2328.HK）20 ...

Equity Research·Company Research·Other Internet Service Tongdao Liepin Group (6100.HK) With AI empowerment, Liepin reshapes the value chain of mid-to-high-end talent services Outperform (Initiation) | Forecast & Valuation | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | | Revenue (RMB mn) | 2,282.16 | 2,051.56 | 2,010.75 | 2,094.45 | | Growth (YoY %) | -13.49 | -10.10 | -1.99 | 4.16 | | Net profit (RMB mn) | 0.75 | 150.52 | 200.27 | 261.50 | | Growth (YoY %) | -98.31 | 19969.26 | 33.05 | 30 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company is expected to experience significant profit elasticity in 2025 despite a substantial decline in profits in 2024 due to one-time expenses and stock incentive costs [6] - The company has a target price based on its current valuation and market conditions, with a projected PE ratio of 8/7/6X for 2025-2027 [6] Financial Summary - In 2024, the company achieved revenue/net profit/operating cash flow of 6.589 billion/0.474 billion/0.996 billion, representing a year-on-year decline of 4.68%/43.06%/36.51% [2] - The net profit decline was primarily due to negative operating leverage and increased expense ratios, including stock incentive expenses of 0.099 billion and an increase of 0.068 billion [2] - The company declared a final dividend of 0.38 HKD per share, with a payout ratio of 55.6% and a dividend yield of 4.97% [2] Brand Performance - The three main brands Koradior, NAERSI, and NEXY.CO experienced revenue growth rates of -9.68%, -1.87%, and 0.79%, respectively, accounting for 69.9% of total revenue [3] - The growth brands La Koradior, ELSEWHERE, CADIDL, and NAERSILING had mixed performance, with La Koradior showing a growth rate of 10.23% [3] - The company saw a total store count decrease of 125 stores in 2024, a decline of 6.4% year-on-year [3] Profitability Metrics - The company's gross margin for 2024 was 76.4%, an increase of 1.1 percentage points year-on-year [4] - The net profit margin for 2024 was 7.1%, a decrease of 5.0 percentage points year-on-year, primarily due to increased expense ratios and decreased other income [4] - The company’s selling, general, and administrative expenses as a percentage of revenue increased, with selling expenses at 59.0%, management expenses at 10.3%, and financial expenses at 0.8% [4] Inventory and Receivables - The company's inventory increased to 1.572 billion, a year-on-year growth of 36%, with inventory to revenue ratio at 24% [5] - Accounts receivable decreased slightly by 0.3% year-on-year to 0.715 billion, while accounts payable increased significantly by 104.4% to 0.306 billion [5] Future Projections - Revenue forecasts for 2025 and 2026 have been adjusted down to 6.980 billion and 7.941 billion, respectively, while the 2027 forecast has been increased to 8.891 billion [6] - The projected net profit for 2025 and 2026 has been revised to 0.628 billion and 0.749 billion, with an increase for 2027 to 0.869 billion [6] - The earnings per share (EPS) estimates for 2025 and 2026 have been adjusted to 0.89 and 1.06, with a new estimate for 2027 at 1.23 [6]

Investment Rating - The report maintains a "Buy" rating for the company [1][6] Core Views - The company achieved a revenue of 6.635 billion yuan in 2024, representing a year-on-year growth of 0.4%, while the net profit attributable to shareholders was 733 million yuan, up 2.6%. The adjusted net profit reached 1.018 billion yuan, marking a significant increase of 41.65% [3][6] - The revenue from innovative drugs reached 4.928 billion yuan, accounting for 74.3% of total revenue, which is the highest since the company's listing [3][6] - The company is set to launch multiple innovative drugs, including Enlitai and Xianbixin, which are expected to significantly contribute to revenue growth [4][5] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 6.635 billion yuan and a net profit of 733 million yuan. The adjusted net profit was 1.018 billion yuan, indicating a robust growth trajectory [3][8] - The projected revenues for 2025, 2026, and 2027 are 7.659 billion yuan, 9.073 billion yuan, and 10.493 billion yuan, respectively, with year-on-year growth rates of 15.43%, 18.47%, and 15.65% [6][8] Innovative Drug Pipeline - The company has received approval for two new innovative drugs in 2024, expanding its portfolio to a total of eight approved innovative drugs. This includes the anticipated launch of Xianbixin, which is expected to enhance treatment options for stroke patients [4][5] - The innovative drug revenue is expected to continue growing, supported by the inclusion of Koseira and Enlitai in the national medical insurance directory, which will facilitate sales growth [4][5] Valuation Metrics - The earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.43 yuan, 0.52 yuan, and 0.62 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 17, 14, and 12 [6][8] - The report suggests that the company's valuation is likely to recover as the revenue from innovative drugs increases and multiple new products are launched [6]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company achieved a revenue of $630.2 million in 2024, with a significant contribution from oncology products, which generated $272 million, reflecting a 65% year-on-year growth [9] - The company has successfully reached financial self-sufficiency ahead of schedule, with a cash balance of $832 million at the end of the previous year [9] - The report highlights the rapid market penetration of the drug Fuzuloparib, with sales of $405 million in 2024, and the ongoing clinical progress of the drug Savolitinib [9] - The company is expanding its product pipeline into autoimmune and hematological malignancies, with new drug applications expected soon [9] Financial Forecast and Investment Recommendations - The revenue forecasts for 2025 and 2026 have been adjusted to $730.03 million and $840.85 million, respectively, down from previous estimates of $844 million and $1 billion [3] - The target price for the company is set at HKD 37.99, based on a price-to-sales ratio of 5.83 for 2025 [3] - The financial projections indicate a significant increase in net profit for 2025, estimated at $468.43 million, representing a year-on-year growth of 1141.58% [5]

Investment Rating - The investment rating for WuXi AppTec (02268.HK) is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 4.052 billion yuan in 2024, representing a year-on-year growth of 86.82%, and a net profit of 1.070 billion yuan, with a year-on-year increase of 277.24% [4][8] - The total amount of unfulfilled orders reached 991 million USD, a year-on-year growth of approximately 71.2%, providing assurance for future performance growth [4] - The company is positioned as a leading CRDMO in the global antibody-drug conjugate (ADC) outsourcing service market, prompting an upward revision of profit forecasts for 2025-2027 [4][5] Financial Performance - Revenue and Profit Forecasts: - 2025: Revenue expected to be 5.471 billion yuan, net profit 1.433 billion yuan, EPS 1.2 yuan - 2026: Revenue expected to be 7.340 billion yuan, net profit 1.932 billion yuan, EPS 1.6 yuan - 2027: Revenue expected to be 9.849 billion yuan, net profit 2.781 billion yuan, EPS 2.3 yuan [4][8] - Financial Ratios: - Gross margin is projected to increase from 30.6% in 2024 to 35.5% in 2027 - Net profit margin is expected to rise from 26.4% in 2024 to 28.2% in 2027 [8][10] Operational Highlights - The company has established three operational bases in Wuxi, Changzhou, and Shanghai, enhancing its product development and supply chain system [6] - The Wuxi base has achieved a significant milestone in "one-stop" production for ADC, simplifying the supply chain and significantly shortening production cycles [6] - The Singapore production base is expected to commence operations by the end of 2025, further expanding global capacity [6] Client Engagement - By the end of 2024, the company served a total of 499 clients, including 13 of the top 20 global pharmaceutical companies, which contributed to 32% of total revenue [4][5]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HK$16.59, corresponding to a PB of 1.2 times for 2025 [6]. Core Views - In 2024, the company achieved a net profit of CNY 32.161 billion, a year-on-year increase of 30.9%, while the underwriting profit decreased by 43.9% to CNY 5.713 billion. The comprehensive cost ratio (COR) rose to 98.8%, an increase of 1.0 percentage points year-on-year [1][3]. - The company’s investment income significantly increased by 67.9% year-on-year to CNY 34.937 billion, primarily due to the strategic allocation of secondary equity assets during market lows [5]. Summary by Sections Performance Overview - In 2024, the company reported a net profit of CNY 32.161 billion, up 30.9% year-on-year, with an underwriting profit of CNY 5.713 billion, down 43.9%. The COR was 98.8%, up 1.0 percentage points, and ROE was 13.0%, up 2.2 percentage points. The proposed final dividend per share is CNY 0.332, leading to a total annual dividend of CNY 0.54, an increase of 10.4% year-on-year [1]. Liability Side - The insurance service revenue for 2024 was CNY 485.223 billion, a year-on-year increase of 6.1%, with a market share of 31.8%, down 0.7 percentage points. The revenue from auto insurance was CNY 294.701 billion, up 4.5%, while non-auto insurance revenue was CNY 190.522 billion, up 8.8% [2][3]. Profitability - The COR increased by 1.0 percentage points to 98.8% in 2024, driven by a rise in the loss ratio, which increased by 2.4 percentage points to 73%. The increase in loss ratio was attributed to severe disaster impacts and rising liability costs due to declining interest rates. The company implemented cost reduction measures, reducing the expense ratio by 1.4 percentage points to 25.8% [3][4]. Investment Side - By the end of 2024, the total investment scale reached CNY 676.512 billion, a 12.6% increase from the previous year, with a total investment return rate of 5.5%, up 2 percentage points year-on-year [5]. Profit Forecast and Valuation - The company aims for steady growth, with projected net profit growth rates of 29.9%, 16.4%, and 20.5% for 2025-2027. The BPS is expected to be CNY 12.57, CNY 14.06, and CNY 15.82 for the respective years, with corresponding PB ratios of 1.04, 0.93, and 0.83 [6][13].